| Subject: | FDA Warns of Increased Risk of Hepatotoxicity with Propylthiouracil (PTU) |
| Category: | Food and Drug Administration (FDA)
|
| Published: | Thu, 4 Jun 2009 - 10:00 am |
| The Food and Drug Administration (FDA) is notifying healthcare professionals of the risk of serious liver injury, including liver failure and death, with the use of propylthiouracil (PTU) in adult and pediatric patients. Reports to FDA's Adverse Event Reporting System (AERS) suggest there is an increased risk of hepatotoxicity with PTU when compared to methimazole (MMI). The FDA has identified 32 (AERS) cases (22 adult and 10 pediatric) of serious liver injury associated with PTU use.... The full article is available to StayAlert subscribers. Click here for a free trial subscription. |
|
RESOURCES:
External Links:
|
|
StayAlert! notifies healthcare customers of all federal and regulatory body legislation changes impacting the healthcare industry, including TJC (JCAHO), CDC, CMS, DHHS, FDA, OSHA, OIG and many others. StayAlert! complements this with regulatory implementation action plans. StayAlert! serves as a virtual healthcare department, augmenting traditional employee staffed departments and freeing employees to perform other vital functions. StayAlert! is the only comprehensive clinical and regulatory service providing organizations in the healthcare arena with practical applications to meet complex mandated federal requirements. |
|
